ITUS Corporation funds, develops, acquires and licenses emerging technologies in areas such as cancer diagnostics, encrypted communications, and semiconductor fabrication. Anixa Diagnostics, a subsidiary of ITUS, is developing a platform for inexpensive, non-invasive blood tests for the screening and early detection of solid tumors. The platform measures a unique set of biomarkers that have been associated with multiple stages and types of cancer. The company's strategy is based on the belief that early detection has the potential to significantly reduce cancer deaths and greatly improve the quality of life for patients. Anixa's long term goal is for its screening tests to become part of the normal battery of tests ordered for asymptomatic patients during routine doctor visits. ITUS's corporate headquarters is located in Los Angeles, California.